Posted by Michael Wonder on 23 Mar 2023
Calquence granted first regulatory approval in China for adults with previously treated mantle cell lymphoma
23 March 2023 - Across two clinical trials 82% overall response and 35% complete response rate were observed in Chinese patients using Calquence.
AstraZeneca’s Calquence (acalabrutinib), a next generation, selective Bruton’s tyrosine kinase inhibitor, has been conditionally approved in China for the treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy.
